Price$25.38+7.24 (+39.91%)
2026-03-042026-06-05
News · 26 weeks63-87%
2025-12-142026-06-07
Mix3190d
- SEC Filings12(39%)
- Other11(35%)
- Insider5(16%)
- Leadership1(3%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- ANALYSTCanaccord Genuity initiated coverage on Pulse Biosciences with a new price targetCanaccord Genuity initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $32.00
- PRPulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences' Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as w
- INSIDERAmendment: Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,370,047 units (SEC Form 4)4/A - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- SECSEC Form 10-Q filed by Pulse Biosciences Inc10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Pulse Biosciences IncSCHEDULE 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)
- PRATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 MillionPulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences' common stock for an aggregate purchase price of approximately $13.3 million. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as w
- INSIDERAmendment: Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69), increasing direct ownership by 1,773% to 15,846 units (SEC Form 4)4/A - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERChief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69) (SEC Form 4)4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERDirector Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,211,433 units (SEC Form 4)4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- SECSEC Form DEF 14A filed by Pulse Biosciences IncDEF 14A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences to Present at the BofA Securities 2026 Healthcare ConferencePulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV. Pulse Biosciences' Management is scheduled to present on Wednesday, May 13, at 4:35 pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential
- SECPulse Biosciences Inc filed SEC Form 8-K: Other Events8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Reports Business Updates and First Quarter 2026 Financial ResultsAccelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonstrating exceptional procedure efficiency and durable outcomes. Pre
- SECAmendment: SEC Form 10-K/A filed by Pulse Biosciences Inc10-K/A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking presentation included incremental participant follow up data. Building upon the previously reported data set presented at the AF Symposium meeting in February of 2026, the expanded 6-
- PRPulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual MeetingnPulse™ Technology highlighted in late-breaking feasibility study and live case transmission Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes of nanosecond PFA using a compliant catheter for the treatment of atrial fibrillation (AF). The Company will also participate in a live c
- PRPulse Biosciences to Host Analyst Event on April 25, 2026Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois. Management will highlight the late-breaking data from its European feasibility study for the treatment of atrial fibrillation and discuss its ongoing clinical program for the nPulse Cardiac Catheter system. The Analyst Event will be held in hybrid format with a simultaneous onlin
- SECPulse Biosciences Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Strengthens Executive Leadership TeamAppoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg's Chief Medical Officer Role Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the strengthening of its executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer and expanded role of Dr. David Kenigsberg as full-time Chief Medical Officer. Both the appointment of Liane Teplitsky as Chief Operating Officer and Dr. David Kenigsberg's agreement to serve as the Company's Chief Medical Officer on a full-time basis further enhance the Company's strategic alignment to priori
- SECPulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial FibrillationU.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF). The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Invest
- INSIDERSEC Form 4 filed by Uecker Darrin4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
PLSE FAQ
7 questionsWhat does Pulse Biosciences Inc do?
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Where does PLSE stock trade?
Pulse Biosciences Inc (PLSE) is listed on NASDAQ.What sector and industry is PLSE in?
Pulse Biosciences Inc operates in the Health Care sector, Medical/Dental Instruments industry.When did Pulse Biosciences Inc go public?
Pulse Biosciences Inc (PLSE) completed its IPO in 2016.What are analysts saying about PLSE?
Pulse Biosciences Inc has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $3200.00 price target on 2026-06-04. Recent price targets range from $2000.00 to $4300.00.What companies are similar to PLSE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PLSE side-by-side with any of them on Quantisnow.How can I track PLSE on Quantisnow?
Quantisnow aggregates Pulse Biosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLSE to receive live email and push alerts on every new disclosure.